Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 May 26;4(2):ofw252.
doi: 10.1093/ofid/ofw252. eCollection 2017 Spring.

Can Hepatitis C Virus Antigen Testing Replace Ribonucleic Acid Polymearse Chain Reaction Analysis for Detecting Hepatitis C Virus? A Systematic Review

Harun Khan  1 , Andrew Hill  2 , Janice Main  1 , Ashley Brown  1 , Graham Cooke  1
Affiliations
Review

Can Hepatitis C Virus Antigen Testing Replace Ribonucleic Acid Polymearse Chain Reaction Analysis for Detecting Hepatitis C Virus? A Systematic Review

Harun Khan et al. Open Forum Infect Dis. .

Abstract

The complexity and cost of current diagnostics for hepatitis C virus (HCV) may act as a prevention to the scale-up of treatment in the developing world. Currently, ribonucleic acid (RNA)-polymerase chain reaction tests are the gold standard. However, there is potential for the use of simpler and cheaper antigen tests to confirm HCV infection in different clinical settings. We evaluated the sensitivity and specificity of antigen assays. This was compared with the reference-standard RNA assays. A subanalysis also assessed Architect core antigen test, which is the only commercially available antigen test on the market. In 24 datasets, evaluating HCV-antigen assays in 8136 samples, the percentage of HCV-antigen positive, HCV-RNA negative was 0.57%. The percentage HCV-antigen negative, HCV-RNA positive was 3.52%. There is strong evidence that antigen detection performs as well as RNA-based assays for HCV management. The use of antigen tests could improve access to HCV care in underresourced healthcare settings.

Keywords: HCV RNA.; HCV antigen; HCV diagnostics.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Flowchart of study selection process (PRISMA Flow Chart 2009) [3].
Figure 2.
Figure 2.
Receiver operator characteristic curve of results from all 24 included publications.
See this image and copyright information in PMC

References

    1. Cooke GS, Hill AM. Diagnostics for resource-limited settings in the era of interferon-free HCV therapy. J Viral Hepat 2015; 22:459–60. - PubMed
    1. UNITAID. Hepatitis C—Diagnostics Technology Landscape Available at: http://unitaid.org/images/marketdynamics/publications/UNITAID-HCV_Diagno.... Accessed 15 August 2016.
    1. PRISMA. PRISMA Statement Available at: http://www.prisma-statement.org/PRISMAStatement/ Accessed 15 August 2016.
    1. Moses L, Shapiro D, Littenberg B. Combining independent studies of a diagnostic test into a summary ROC curve: data‐analytic approaches and some additional considerations. Stat Med 1993; 12:1293–316. - PubMed
    1. Whiting P, Rutjes A, Westwood ME, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 2011; 155:529–36. - PubMed